-
1 Comment
iRhythm Technologies, Inc is currently in a long term downtrend where the price is trading 61.1% below its 200 day moving average.
From a valuation standpoint, the stock is 98.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 14.3.
iRhythm Technologies, Inc's total revenue rose by 33.3% to $79M since the same quarter in the previous year.
Its net income has increased by 44.2% to $-10M since the same quarter in the previous year.
Finally, its free cash flow grew by 132.7% to $5M since the same quarter in the previous year.
Based on the above factors, iRhythm Technologies, Inc gets an overall score of 4/5.
Exchange | NASDAQ |
---|---|
CurrencyCode | USD |
ISIN | US4500561067 |
Sector | Healthcare |
Industry | Medical Devices |
Market Cap | 3B |
---|---|
PE Ratio | None |
Target Price | 130.9167 |
Beta | 1.45 |
Dividend Yield | None |
iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IRTC using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025